BARD1 Life Sciences (ASX:BD1) has entered into a collaboration with the Institute for Respiratory Health (IRH) to evaluate a BARD1 cancer vaccine for the prevention and/or treatment of cancer in animal models.
The company said the project will evaluate various of its formulations across several fully characterised tumour cell lines to determine their effectiveness in preventing tumour growth or reducing tumour size in two industry-accepted tumour models in mice.
"Additionally, the project will determine the optimal dose and timing for vaccination, and other secondary outcomes. BARD1 LSL has the option to terminate or extend the project depending on various milestones and outcomes," said the company.
Dr Leearne Hinch, CEO of BARD1 LSL, said: “This agreement gives us the opportunity to explore the therapeutic potential of our BARD1 Technology. We have already demonstrated the utility of this technology in the diagnostic area, but therapeutic applications offer a large upside potential and, if the animal studies demonstrate effectiveness, this collaboration will enable us to advance our therapeutic program towards preclinical development.”
The Perth-based Institute for Respiratory Health, is a collaborative respiratory research organisation focused on respiratory illnesses including cancers of the lung. This collaboration expands on previous research conducted by BARD1 LSL’s Chief Scientific Officer, Dr Irmgard Irminger-Finger in experimental models.
Professor Geoff Laurent, Director of the Institute for Respiratory Health added: “We believe the BARD1 Technology has much to offer in the field of therapeutic vaccines for lung cancer. This is precisely the kind of mutually beneficial research collaboration that, if successful, will expand the therapeutic options for cancer patients.”